Actively Recruiting
Evaluating Empasiprubart IV Added to Efgartigimod IV in Adults With AChR-Ab Seropositive Generalized Myasthenia Gravis Showing Partial Response to Efgartigimod
Led by argenx · Updated on 2026-09-24
70
Participants Needed
33
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and therapeutic relevance of empasiprubart as an add-on treatment to efgartigimod in people with acetylcholine receptor antibody AChR-Ab seropositive generalized myasthenia gravis who have only partially responded to efgartigimod. This Phase 2a exploratory study is part of the larger ADAPT Forward platform, aiming to find safer and more effective treatment approaches to reduce side effects and improve quality of life for patients with myasthenia gravis. Participants first enter a run-in period where they receive intravenous efgartigimod. Those eligible then move to the add-on period, receiving both efgartigimod and empasiprubart intravenously. Participants not eligible for the add-on phase continue with efgartigimod alone during the safety follow-up period. The entire study duration for each participant lasts up to about 54 weeks. Throughout the study, participants are closely monitored with assessments including adverse event tracking, muscle strength and function evaluations, and quality of life questionnaires. The primary outcome is the incidence of adverse events during the first 21 weeks, with secondary measures examining changes in clinical scores such as MG-ADL and QMG. Safety follow-up continues for those not in the add-on phase to ensure ongoing monitoring of treatment effects.
CONDITIONS
Brief Title
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Research Team
S
Sabine Coppieters, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here